ArticleCancers2022

Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies.

Manish A Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.